背景:口腔扁平苔藓(OLP)是一种慢性皮肤粘膜免疫介导的疾病,对口腔功能有很大的不利影响。皮质类固醇仍然是用于治疗OLP的首选药物;然而,它们有广泛的医学副作用。本研究旨在评估局部使用辅酶Q10(辅酶Q10或泛醇)与局部使用皮质类固醇在有症状的OLP治疗中的临床治疗效果,并确定其效果是否,如果有的话,是由于coQ10强大的抗氧化活性。
方法:我们进行了随机,牙科学院的双盲对照试验,开罗大学,埃及。这项研究是对34名患有症状性OLP的患者进行的。将患者随机分为两组:干预组(I)、谁以粘膜粘附片剂(40%CoQ10)的形式接受局部CoQ10,每天3次,持续一个月,对照组(II),谁接受了局部皮质类固醇(orabase中的kenacort:曲安奈德0.1%5-g粘合膏-dermaharm),每天4次,持续一个月。使用疼痛(VAS)和病变大小的临床参数(评分)以一周的间隔评估患者。此外,采用ELISA法检测两组治疗前后唾液丙二醛(MDA)水平.所有记录的数据使用独立t检验进行分析,ANOVA,然后进行Bonferroni事后检验,以了解病变大小和唾液水平的MDA数据,以及VAS数据的Mann-WhitneyU检验和Friedman检验。
结果:两组均显示疼痛和病变大小显着减少(p≤0.05),两者之间无统计学差异(p>0.05),这种临床改善与两组唾液MDA水平的降低有关。
结论:局部使用CoQ10粘膜粘附片剂与局部使用曲安奈德一样有效,其临床效果与唾液MDA水平降低有关。
背景:研究方案在www注册。
背景:gov(NCT04091698),注册日期:2019年9月17日。
Oral lichen planus (OLP) is a chronic mucocutaneous immunologically mediated condition that has a great adverse effect on oral functions. Corticosteroids are still the first drugs of choice used in the treatment of OLP; however, they have extensive medical side effects. The present
study was carried out to assess the clinical therapeutic effect of the topical use of coenzyme Q10 (coQ10 or ubiquinol) versus topical corticosteroids in the management of symptomatic OLP and to determine whether the effect, if any, was due to the powerful antioxidant activity of
coQ10.
We performed a randomized, double blinded controlled
trial at the Faculty of Dentistry, Cairo University, Egypt. The
study was conducted on 34 patients suffering from symptomatic OLP. Patients were randomly divided into two groups: intervention group (I),who received topical CoQ10 in the form of mucoadhesive tablets (40% CoQ10) 3 times daily for one month and control group (II),who received topical corticosteroid (kenacort in Orabase: triamcinolone acetonide 0.1% 5-g adhesive paste - dermapharm), 4 times daily for one month. Patients were evaluated at one-week intervals using the clinical parameters (score) of pain (VAS) and lesion size. Additionally, salivary levels of malondialdehyde (MDA) were detected in both groups before and after treatment using ELISA. All recorded data were analysed using independent t test, ANOVA followed by Bonferroni post hoc test for lesion size and salivary level of MDA data and Mann-Whitney U test and Friedman test for VAS data.
Both groups showed a significant reduction in pain and the size of the lesions (p ≤ 0.05) with no statistically significant difference between them (p > 0.05), and this clinical improvement was associated with a reduction in the salivary levels of MDA in both groups.
The topical use of CoQ10 mucoadhesive tablets was as effective as the topical use of triamcinolone acetonide, and its clinical effect was associated with a reduction in the salivary level of MDA.
The
study protocol was registered at www.
gov (NCT04091698) and registration date: 17/9/2019.